Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summi
Summit Therapeutics Stock Dips After Q1 Financial Report
11:12am, Friday, 01'st May 2026
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
04:32pm, Thursday, 30'th Apr 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational prog
Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fueled broad gains.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
12:30pm, Thursday, 16'th Apr 2026
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst
02:27pm, Wednesday, 08'th Apr 2026
Ivonescimab is a PD-1xVEGF bispecific antibody under development for cancer, primarily for lung cancer.
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT
03:09am, Tuesday, 07'th Apr 2026
Aberdeen Group plc lowered its stake in Summit Therapeutics PLC (NASDAQ: SMMT) by 18.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Summit Therapeutics (NASDAQ:SMMT) and Cosmos Health (NASDAQ:COSM) Financial Contrast
01:25am, Tuesday, 07'th Apr 2026
Summit Therapeutics (NASDAQ: SMMT - Get Free Report) and Cosmos Health (NASDAQ: COSM - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two compan
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
08:15am, Friday, 27'th Mar 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigation
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
04:22pm, Wednesday, 11'th Mar 2026
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Citigroup Inc. Acquires 46,535 Shares of Summit Therapeutics PLC $SMMT
04:20am, Friday, 06'th Mar 2026
Citigroup Inc. increased its holdings in Summit Therapeutics PLC (NASDAQ: SMMT) by 41.1% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 15
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04:57pm, Monday, 02'nd Mar 2026
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Summit Therapeutics (NASDAQ:SMMT) and Wellgistics Health (NASDAQ:WGRX) Head to Head Comparison
02:20am, Saturday, 28'th Feb 2026
Wellgistics Health (NASDAQ: WGRX - Get Free Report) and Summit Therapeutics (NASDAQ: SMMT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two comp
Summit Therapeutics to Present at Upcoming Investor Conferences
06:45pm, Thursday, 26'th Feb 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
12:36pm, Tuesday, 24'th Feb 2026
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
